3% Polidocanol Sclerotherapy for Pyogenic Granuloma: Efficacy and Safety Analysis

INTRODUCTION: Pyogenic granuloma is a commonly occurring inflammatory hyperplasia involving skin and mucous membranes. Various modalities of treatment have been used to treat pyogenic granuloma. However, there is an increased risk of intraoperative bleeding and recurrence of pyogenic granuloma following surgical treatment of pyogenic granuloma. Therefore, sclerotherapy has evolved as an effective alternative treatment modality in excellent safety and efficacy. AIMS AND OBJECTIVES: The aim of this study was to assess the safety and efficacy of 3% polidocanol in liquid form in pyogenic granuloma as a sclerosant. SETTINGS AND DESIGN: This was a retrospective study of cases treated between March 2019 and February 2020 at two different private institutes. MATERIALS AND METHODS: The study included 30 patients with 30 pyogenic granulomas treated with 3% polidocanol liquid. Individuals with comorbid conditions such as diabetes, hypertension, thyroid disorders, and those who were on medications were excluded from the study. Two units of 3% polidocanol solution were injected with an insulin syringe at the base of the lesion. Changes in lesions and adverse events were recorded and injections were repeated after a gap of 2 weeks if needed. RESULT: In 28 patients, there was complete resolution of the lesion within 4 weeks and 2 patients received a second injection of polidocanol. All the patients tolerated the procedure and the lesions resolved without any significant sequelae. DISCUSSION: The advantages of 3% polidocanol sclerotherapy are that it is a safe, easy, effective, and minimally invasive procedure with little discomfort to the patient and very minimal complications as compared with other modalities. CONCLUSION: Polidocanol 3% solution is an effective sclerosant for the treatment of pyogenic granuloma. The aim of this study was to assess the safety and efficacy of 3% polidocanol in the liquid form in PG as a sclerosant.